How AI is Changing IBD Care | Interview with Dr. Michael Byrne

Two doctors can score the same colonoscopy video differently; so can one doctor at the beginning and end of a day. In inflammatory bowel disease (IBD), this inconsistency can affect who qualifies for clinical trials, whether a drug looks like it’s working, and how patients are treated. Watch our conversation with Dr. Michael Byrne, Founder and Chief Medical Officer (CMO) of Dova Health Intelligence and gastroenterologist of over 30 years. He discusses the crucial opportunity for AI to assist physicians rather than replace them, how AI brings more consistency to IBD care from scoring every colonoscopy frame to re-reading clinical trial results, and its potential to move care from beyond simple disease detection and into quantification. FOLLOW US • Website: https://dovahealth.ca • LinkedIn:   / dovahealth   • Dr. Michael Byrne's LinkedIn:   / michael-byrne-satisfai   • X: https://x.com/dovahealthIQ • Book a Meeting: https://www.dovahealth.ca/leads ABOUT DOVA Dova is a precision health technology company that is building the AI infrastructure for how gastrointestinal (GI) health is measured, monitored, and managed. We develop AI-powered, image-based solutions that empower clinicians and researchers with actionable insights to advance GI care. Our multimodal intelligence platform includes DovaVision UC, designed to support granular assessment of ulcerative colitis at scale, and DovaSound, designed to support rapid, standardized intestinal ultrasound image capture and assessment. Learn more about our dual-modal intelligence platform for IBD: https://www.dovahealth.ca